Lv43
640 积分 2025-03-22 加入
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma
2天前
已完结
Treatment Decisions in Multiple Myeloma
4天前
已完结
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
6天前
已完结
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
6天前
已完结
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis
6天前
已完结
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
6天前
已完结
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
6天前
已完结
Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial
7天前
已完结
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial
8天前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
19天前
已完结
皖公网安备34019202002308
